Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas.
Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas.
复制标题
5-氟尿嘧啶、阿霉素和丝裂霉素 C 与单独使用 5-氟尿嘧啶治疗胰胆管癌的比较。
作者：
Tadahiro Takada;Hiroyuki Kato;Takashi Matsushiro;Yuji Nimura;T. Nagakawa;T. Nakayama
在这项多中心随机试验中，在81例不能切除的胰腺癌或胆道癌患者中，比较了5-氟尿嘧啶、多柔比星和丝裂霉素C联合化疗（A组）与5-氟尿嘧啶单用（B组）的疗效。治疗组之间在至疾病进展的中位时间、中位生存时间、姑息效应或毒性方面无显著差异。结论：联合化疗是可行的，但不能推荐。
In this multicenter randomized trial, the efficacy of combination chemotherapy using 5-fluorouracil, doxorubicin and mitomycin C (arm A) was compared with that of 5-fluorouracil alone (arm B) in 81 patients with nonresectable carcinomas of the pancreas or biliary tract. There were no significant differences between treatment arms regarding the median time to progressive disease, median survival time, palliative effects or toxicities. It was concluded that combination chemotherapy is feasible but cannot be recommended.